| Uveitis
Hyrimoz vs Ozurdex
Side-by-side clinical, coverage, and cost comparison for uveitis.Deep comparison between: Hyrimoz vs Ozurdex with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOzurdex has a higher rate of injection site reactions vs Hyrimoz based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ozurdex but not Hyrimoz, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyrimoz
Ozurdex
At A Glance
SC injection
Every other week
TNF-alpha antagonist
Intravitreal injection
Corticosteroid
Indications
- Rheumatoid Arthritis
- Juvenile rheumatoid arthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Crohn Disease
- Ulcerative Colitis
- Psoriasis Vulgaris
- Hidradenitis
- Uveitis
- Macular retinal edema
- Uveitis
Dosing
Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some RA patients not receiving MTX may benefit from 40 mg every week or 80 mg every other week.
Juvenile rheumatoid arthritis Weight-based SC dosing every other week for patients >=2 years: 10 mg (10 to <15 kg), 20 mg (15 to <30 kg), or 40 mg (>=30 kg); same dosing applies to pediatric uveitis patients.
Crohn Disease Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; pediatric patients >=6 years receive weight-based loading doses followed by 20 or 40 mg every other week.
Ulcerative Colitis Adults: 160 mg on Day 1, 80 mg on Day 15, then 40 mg SC every other week starting Day 29; discontinue if no clinical remission by Day 57.
Psoriasis Vulgaris, Uveitis 80 mg initial SC dose, then 40 mg every other week starting one week after initial dose.
Hidradenitis Adults: 160 mg Day 1, 80 mg Day 15, then 40 mg every week or 80 mg every other week SC starting Day 29; adolescents >=12 years receive weight-based dosing (80 mg Day 1 for 30 to <60 kg, or 160 mg Day 1 for >=60 kg).
Macular retinal edema, Uveitis One 0.7 mg intravitreal implant injected into the vitreous cavity under controlled aseptic conditions; each applicator is single-use and treats one eye only.
Contraindications
—
- Active or suspected ocular or periocular infections, including viral diseases of the cornea and conjunctiva (active epithelial herpes simplex keratitis, vaccinia, varicella), mycobacterial infections, and fungal diseases
- Glaucoma with cup to disc ratios greater than 0.8
- Torn or ruptured posterior lens capsule due to risk of migration into the anterior chamber
- Known hypersensitivity to any components of this product
Adverse Reactions
Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, abdominal pain, back pain, urinary tract infection, flu syndrome, accidental injury, hypertension.
Serious Serious infections (pneumonia, septic arthritis, erysipelas, cellulitis, diverticulitis, pyelonephritis), malignancies, hypersensitivity reactions, hepatitis B reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity.
Postmarketing Diverticulitis, large bowel perforations, pancreatitis, liver failure, autoimmune hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, systemic vasculitis, deep vein thrombosis.
Most common (>=20%) Cataract, increased intraocular pressure, conjunctival hemorrhage
Serious Elevated IOP with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection (including herpes simplex), globe perforation
Postmarketing Endophthalmitis, retinal detachment, implant misplacement with ocular tissue injury, device dislocation with corneal edema or decompensation, hypotony of the eye
Pharmacology
TNF-alpha antagonist; adalimumab-adaz is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, also lysing surface TNF-expressing cells in vitro in the presence of complement.
Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting multiple inflammatory cytokines, resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyrimoz
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Ozurdex
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Hyrimoz
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Ozurdex
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Hyrimoz
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ozurdex
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hyrimoz.
No savings programs available for Ozurdex.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyrimozView full Hyrimoz profile
OzurdexView full Ozurdex profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.